Becton, Dickinson (BDX) said it has applied for a CE Mark in the European Union for its Liverty TIPS Stent Graft, a next-generation device designed to treat complications from portal hypertension in the liver.

The company said the device targets patients with cirrhosis, a condition affecting an estimated 58 million people globally, and aims to improve outcomes by reducing elevated blood pressure in the liver through TIPS procedures.

The Liverty stent features an adjustable diameter, flexible self-expanding frame, and advanced coating designed for precision placement and durability, the company added.